Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
RAS mutations are common in myeloid malignancies; however, it is not known whether oncogenic RAS can initiate leukemia. We show that expressing mutant K-Ras(G12D) protein from the endogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance characterized by tissue infiltration, hypersensitivity to growth factors, and hyperproliferation. Hematopoietic cells from diseased mice demonstrated increased levels of Ras-GTP, but effector kinases were not constitutively phosphorylated and responded normally to growth factors. Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
The GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Proteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,901
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationThiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Research works printed but not linked: 6
- Bos, J. L. (1989) Cancer Res. 49, 4682-4689.
- Padua, R. A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F. & Jacobs, A. (1988) Leukemia 2, 503-510.
- Bashey, A., Gill, R., Levi, S., Farr, C. J., Clutterbuck, R., Millar, J. L., Pragnell, I. B. & Marshall, C. J. (1992) Blood 79, 981-989. · doi:10.1182/blood.v79.4.981.bloodjournal794981
- Dunbar, C. E., Crosier, P. S. & Nienhuis, A. W. (1991) Oncogene Res. 6, 39-51.
- Hawley, R. G., Lieu, F. H., Fong, A. Z. & Hawley, T. S. (1994) Gene Ther. 1, 136-138.
- Donovan, S., Shannon, K. M. & Bollag, G. (2002) BBA Rev. Cancer. 1602, 23-45.
Cited by
Items 201–300 of 308
Acute sensitivity of the oral mucosa to oncogenic K‐ras
van der Weyden, L., Alcolea, M. P., Jones, P. H., Rust, A. G., Arends, M. J., & Adams, D. J. (2011) · The Journal of Pathology · doi:10.1002/path.2853 · Cited by 14
Role of PTPN11 (SHP2) in Cancer
Chan, G., & Neel, B. G. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3649-6_4 · Cited by 14
Xiao, J., Lee, S., Xiao, Y., Ma, X., Houseman, E. A., Hsu, L., Roy, R., Wrensch, M., de Smith, A. J., Chokkalingam, A. P., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28759 · Cited by 13
Genetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer
Rappaport, A., & Johnson, L. (2014) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069799 · Cited by 14
“Similarly, mouse models of squamous cell carcinoma of the skin, colon cancer, and hematopoietic malignancies have been generated by crossing conditional KI mice containing the LSLKras allele with the appropriate tissue-specific, Cre-expressing strain (Braun et al. 2004; Caulin et al. 2007; Haigis et al. 2008; Hung et…”
MethodPati, H., & Veetil, K. K. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01084-y · Cited by 12
Kandarpa, M., Robinson, D. R., Wu, Y., Qin, T., Pettit, K. M., Li, Q., Luker, G. D., Sartor, M. A., Chinnaiyan, A. M., & Talpaz, M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0372 · Cited by 13
“The RAS – ERK pathway and its crosstalk with the PI3K pathway promote cell survival, growth, proliferation, and plasticity in many different cancers including hematologic malignancies (25, 41).”
Oßwald, L., Hamarsheh, S., Uhl, F. M., Andrieux, G., Klein, C., Dierks, C., Duquesne, S., Braun, L. M., Schmitt-Graeff, A. H., Duyster, J., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0275 · Cited by 12
“In mice, conditional expression of oncogenic Kras from its endogenous promoter induces a myeloproliferative disease resembling human CMML and JMML (18, 19).”
BackgroundGerminal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
Mullins, C. D., Su, M. Y., Hucthagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D. V., Vij, R., & Tomasson, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067941 · Cited by 12
“In fact, T-cell lymphomas and lung adenomas have been described in Kras mice with Cre expressed via adenovirus and Mx-1 respectively [14,15,26].”
BackgroundMethodTanaka, H., Tamura, A., Sekai, M., Hamazaki, Y., & Minato, N. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01850.x · Cited by 15
Pomeroy, E. J., Lee, L. A., Lee, R. D. W., Schirm, D. K., Temiz, N. A., Ma, J., Gruber, T. A., Díaz-Flores, E., Moriarity, B. S., Downing, J. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.471 · Cited by 14
Self-citationLethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation
Kratz, C. P., Nathrath, M., Freisinger, P., Dressel, P., Assmuss, H.-P., Klein, C., Yoshimi, A., Burdach, S. E. G., & Niemeyer, C. M. (2005) · European Journal of Pediatrics · doi:10.1007/s00431-005-0031-x · Cited by 11
“In addition, somatic activation of oncogenic Kras, a lesion commonly found in JMML, leads to splenomegaly with erythroid infiltration and anemia, which is explained by ineffective erythropoiesis [4, 6].”
BackgroundShen, S., Passioura, T., Symonds, G. P., & Dolnikov, A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.02.011 · Cited by 12
Hochstetler, C. L., Feng, Y., Saçma, M., Davis, A. K., Rao, M., Kuan, C.-Y., You, L., Geiger, H., & Zheng, Y. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.10.003 · Cited by 10
Esposito, M. T. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000195 · Cited by 11
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
Fontana, D., Gambacorti-Passerini, C. B., & Piazza, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756348 · Cited by 11
New pieces of a puzzle: The current biological picture of MPN
Kleppe, M., & Levine, R. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.002 · Cited by 9
Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice
Zamorano-Domínguez, E., Morales-Cacho, L., Barrero, R., Jiménez-Parrado, S., Dhawahir, A., Hernández-Porras, I., Simón-Carrasco, L., Barrambana, S., Sun, P., Galván-del-Rey, A., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2512404122 · Cited by 8
“Interestingly, expression of wild - type and oncogenic Kras have opposite effects, as oncogenic Kras expression in HSCs induces fatal myeloproliferative diseases in mice ( 33 ).”
Zhang, J., Ranheim, E. A., Du, J., Liu, Y., Wang, J., Kong, G., & Zhang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.653154 · Cited by 8
“However, in t(8;21)-induced acute myeloid leukemia (AML), GM-CSF is found to reduce the replating ability of RUNX1-ETO-expressing cells and therefore has a negative impact on leukemogenesis; expression of RUNX1-ETO in c / cells leads to a high penetrance of AML (37).”
BackgroundFerreira, J. P., Lawhorn, I. E. B., Peacock, R. W. S., & Wang, C. L. (2011) · Integrative Biology · doi:10.1039/c1ib00082a · Cited by 8
Wehbe, Z., Ghanjati, F., & Flotho, C. (2021) · Cells · doi:10.3390/cells10092335 · Cited by 8
“Other Cells 2021, 10, 2335 3 of 17 models used knock-in strategies to manipulate the Ptpn11 [45,46] or Kras [47,48] genes.”
MethodInfluentialChang, Y. I., Kong, G., Ranheim, E. A., Tu, P. S., Yu, Y., & Zhang, J. (2017) · PubMed Central · Cited by 13
CBL mutations do not frequently occur in paediatric acute myeloid leukaemia
Coenen, E. A., Driessen, E. M. C., Zwaan, C. M., Starý, J., Baruchel, A., de Haas, V., de Bont, E. S. J. M., Reinhardt, D., Kaspers, G. J. L., Arentsen-Peters, S. T. C. J. M., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12068 · Cited by 7
“This is important, as RAS-pathway activation is known to play an important proliferative role in paediatric AML, which can be targeted by currently available therapy, such as MEK-inhibitors (Meshinchi et al, 2003; Braun et al, 2004; Goemans et al, 2005; Sabnis et al, 2009; Balgobind et al, 2011a).”
BackgroundIncreased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis
Karra, L., Romero–Moya, D., Ksionda, O., Krush, M., Gu, Z., Mues, M., Depeille, P., Mullighan, C. G., & Roose, J. P. (2020) · Oncogene · doi:10.1038/s41388-020-01469-8 · Cited by 8
“To mimic a physiological in vivo situation of competition for limited amounts of available cytokines in the BM niche, we exploited cytokine-bare medium M3231 [11].”
BackgroundMethodInfluentialKamata, T., Dankort, D. L., Kang, J., Giblett, S. M., Pritchard, C. A., McMahon, M., & Leavitt, A. D. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0294 · Cited by 7
Baker, S. J., Cosenza, S. C., Reddy, M. V. R., & Reddy, E. P. (2019) · Oncotarget · doi:10.18632/oncotarget.26735 · Cited by 7
“These mice develop of an aggressive and lethal myeloproliferative neoplasm (MPN) with rapid onset and present with severe anemia, hepatosplenomegaly and leukocytosis [14].”
BackgroundMethodInfluentialNf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia
Morales, C. E., Stieglitz, E., Kogan, S. C., Loh, M. L., & Braun, B. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003754 · Cited by 7
“By contrast, JMML models using Kras or Ptpn11 have more severe phenotypes that might obscure cooperative effects, and Nras mice develop diverse hematopoietic neoplasms.(24-26) In addition, we noted that the incidence and number of cooperating mutations were greater in JMML with NF1 loss than in cases with other canoni…”
BackgroundSelf-citationMouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
Mohanty, S., & Heuser, M. (2021) · Cancers · doi:10.3390/cancers13246192 · Cited by 6
“KRAS KRAS G12D-ND [38] KRAS G12DMPN [39,40] Kras−/− -Embryonic lethal [41,42]”
BackgroundManipulation of DNA Repair Proficiency in Mouse Models of Colorectal Cancer
McIlhatton, M. A., Boivin, G. P., & Groden, J. L. (2016) · BioMed Research International · doi:10.1155/2016/1414383 · Cited by 6
“Although the LSL K-RasG12D model was initially used to investigate Ras involvement in lung tumorigenesis, it was quickly coopted for studies in other cancers including leukemia [113], squamous cell carcinoma [114], and of course colorectal cancer [115, 116].”
MethodMouse Models of Myeloid Malignancies
Basheer, F., & Vassiliou, G. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035535 · Cited by 7
Munteanu, R. A., Gulei, D., Moldovan, C. S., Azzoni, E., Belver, L., Feder, R., Pîrv, S., Buzoianu, A. D., Einsele, H., Mittelman, M., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07861-0 · Cited by 5
Shannon, K., & Li, Q. (2011) · Blood · doi:10.1182/blood-2010-12-320721 · Cited by 5
Self-citationAdvances in the Development of Animal Models of Myeloid Leukemias
Guryanova, O. A., & Levine, R. L. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.03.027 · Cited by 5
Mouse Model for ‐Induced Leukemogenesis
Parikh, C., & Ren, R. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)00402-8 · Cited by 5
“Indeed, it has been shown that the expression of oncogenic K as well as NRAS in murine models can rapidly induce myeloid malignancies with complete penetrance (Braun et al., 2004; Chan et al., 2004; Parikh et al., 2006).”
BackgroundZheng, H., Zhao, P., Tan, Z., Yu, W., Werner, J., Stieglitz, E., Porter, C. C., Chandrakasan, S., Wechsler, D. S., Méndez‐Ferrer, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116087 · Cited by 4
“5–8 JMML arises from an HSC harboring a genetic mutation, but the molecular mechanisms by which the initially mutated stem cell acquires a competitive advantage and evades immune surveillance remain unexplored.”
Karra, L., Finger, A., Shechtman, L. A., Krush, M., Huang, M., Prinz, M., Tenvooren, I., Bahl, K., Hysienaj, L., García-González, P. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014411 · Cited by 4
“19 It should also be noted that pIpC injection of NRas G12D/WT /Mx1CRE mice has been reported to yield a very mild, delayed myeloproliferative neoplasm, 1,23,43,44 with similarities to RoLoRiG/Mx1CRE mice.”
Yin, Z., Su, R., Ge, L., Wang, X., Yang, J., Huang, G., Li, C., Liu, Y., Zhang, K., Deng, L., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.76993 · Cited by 6
“CD52 is a unique gene in GMP2 and has critical effects on MDS [34].”
InfluentialContext dependent roles for RB-E2F transcriptional regulation in tumor suppression
Thwaites, M. J., Cecchini, M. J., Passos, D. T., Zakirova, K., & Dick, F. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0203577 · Cited by 5
Acute Myeloid Leukemia Stem Cells—Updates and Controversies
Chung, S. S., & Park, C. Y. (2014) · Wiley eBooks · doi:10.1002/9781118356203.ch11 · Cited by 4
Noonan syndrome: lessons learned from genetically modified mouse models
Schuhmacher, A. J., Hernández-Porras, I., García-Medina, R., & Guerra, C. E. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1361821 · Cited by 4
“Interestingly, K-Ras mice develop MPD [56], as well as K-Ras mice [59,86].”
BackgroundWandler, A. M., & Shannon, K. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031526 · Cited by 4
“To examine the effects of oncogenic Kras expression in the hematopoietic compartment, two groups intercrossed LSL-KrasG12D and Mx1-Cre mice (Braun et al. 2004; Chan et al. 2004).”
BackgroundInfluentialSelf-citation5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies
Wong, J. C. Y., Weinfurtner, K. M., Westover, T., Kim, J., Lebish, E. J., Alzamora, M. D. P., Huang, B. J., Walsh, M. P., Abdelhamed, S., Ma, J., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02205-x · Cited by 3
Self-citationUeda, S., Sakata, N., Muramatsu, H., Sakaguchi, H., Wang, X., Xu, Y., Kojima, S., Yamaguchi, T., Higa, T., & Takemura, T. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1638-3 · Cited by 3
Lack of KRAS Gene Mutations in Chronic Myeloid Leukemia in Iran
Kooshyar, M. M., Ayatollahi, H., Keramati, M. R., Sadeghian, M. H., Miri, M., & Sheikhi, M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.11.6653 · Cited by 3
“…many hematopoietic growth factor signaling and in hematologic neoplasms and a wide range of variation in frequency of RAS mutations have been observed in hematologic neoplasms (Ahuja et al., 1990; Braun et al., 2004); however RAS role in leukemogenesis is not completely clear (Baum and Ren, 2008).”
BackgroundChronic myeloproliferative disorders
Niemeyer, C. M., & Locatelli, F. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.020 · Cited by 4
Murine Models of Hematopoietic Disease: Pathologic Analysis and Characterization
Lee, B. H., & Kutok, J. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_3 · Cited by 3
Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma
Mansour, M. R. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.3 · Cited by 3
The sum is greater than the FGFR1 partner
Braun, B. S., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00060-1 · Cited by 3
Self-citationInduction of Histiocytic Sarcoma in Mouse Skeletal Muscle
Liu, J., Hettmer, S., Milsom, M. D., Hofmann, I., Hua, F., Miller, C. M., Bronson, R. T., & Wagers, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044044 · Cited by 3
“nations employed here [25,41–43], it is reasonable to expect that culture conditions had only a minor impact on the lineage decision”
BackgroundKoh, C. P., Bahirvani, A. G., Wang, C. Q., Yokomizo, T., Ng, C. E. L., Du, L., Tergaonkar, V., Voon, D. C., Kitamura, H., Hosoi, H., et al. (2022) · Gene · doi:10.1016/j.gene.2022.147049 · Cited by 3
Targeting Hyperactive Ras Signaling in Pediatric Cancer
Levinson, A. L., Shannon, K., & Huang, B. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041572 · Cited by 3
Self-citationDecker, M., Huang, B. J., Ware, T. B., Boone, C. D., Tang, M., Ybarra, J., Sale, M. J., Francois, R. A., Ballapuram, A. C., Taran, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.20.644389 · Cited by 4
“…(CFU-GM) progenitor growth and hypersensitivity to low concentrations of granulocyte-macrophage colony stimulating factor (GM-CSF) in methylcellulose cultures are cellular hallmarks of JMML that are also observed in bone marrow cells from Kras G12D and Nras G12D knock-in mice 35-37 .”
Self-citationAn ultra-sensitive method to detect mutations in human RAS templates
Li, S., & Counter, C. M. (2022) · Small GTPases · doi:10.1080/21541248.2022.2083895 · Cited by 2
Lin, H.-T., Takagi, M., Kubara, K., Yamazaki, K., Michikawa, F., Okumura, T., Naruto, T., Morio, T., Miyazaki, K., Taniguchi, H., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03723-2 · Cited by 2
“Besides studies examining the impact of heterozygous mutation of NRAS (G12D) [43] or KRAS (G12D) [44, 45] for murine HPCs, to the best of our knowledge, this is the first study to analyze the effects of an oncogenic RAS protein expressed under endogenous control in the context of non-immortalized,…”
BackgroundProgression and perspectives in disease modeling for Juvenile myelomonocytic leukemia
Fu, S., Guo, Y., Peng, Z., Zhang, D., Chang, Z., Xiao, Y., Zhang, Q., Yu, L., Chen, C., Chen, Y., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02549-5 · Cited by 2
Jang, G., Park, R., Esteva, E., Hsu, P.-F., Feng, J., Upadhaya, S., Sawai, C. M., Aifantis, I., Fooksman, D., & Reizis, B. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20240587 · Cited by 3
NF1 Mutations in Hematologic Cancers
Chang, T. Y., & Shannon, K. (2012) · Springer eBooks · doi:10.1007/978-3-642-32864-0_30 · Cited by 2
“UsingMx1-Cre to activate endogenous oncogenic Kras expression causes a JMML-likeMPN in mice, which progresses rapidly, leading to death by 4 months of age (Braun et al. 2004; Chan et al. 2004).”
BackgroundSelf-citationBiochemical and Biological Functions of Isoprenylcysteine Carboxyl Methyltransferase
(2011) · The Enzymes · doi:10.1016/b978-0-12-415922-8.00004-5 · Cited by 4
“Mx1-Cre;LSL-KRAS mice that were wild type for Icmt [82,83] were found to develop a fatal myeloproliferative disorder with 100% penetrance after injection with pI–pC.”
BackgroundMyeloproliferative Disease and Cancer in Persons with Noonan Syndrome and Related Disorders
(2008) · Monographs in human genetics · doi:10.1159/000164848 · Cited by 2
KRasG12D-evoked leukemogenesis does not require β-catenin
Ng, C. E. L., Sinha, A., Krivtsov, A. V., Dias, S., Chang, J. C., Armstrong, S. A., & Kalaitzidis, D. (2013) · Leukemia · doi:10.1038/leu.2013.328 · Cited by 2
Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML)
Lauchle, J., & Braun, B. S. (2010) · Springer eBooks · doi:10.1007/978-0-387-69062-9_7 · Cited by 2
“Similar conditional alleles have also been used to model effects of dominant oncogenes such as Kras and Ptpn11 ( Braun et al. 2004; Chan et al. 2004, 2009).”
Self-citationAhmad, E., Gawish, H. H., Alazizi, N. M., & Elhefni, A. M. (2009) · PubMed · Cited by 1
Rodriguez, D. G., Luque, G., Fiora, M. B., Andreoli, V., Sanchez, A. V., & Basquiera, A. L. (2024) · The Hematologist · doi:10.1182/hem.v21.6.202461 · Cited by 1
The Role of MicroRNAs in Hematopoietic Stem Cells and Leukemia Development
Yalcin, S., Chung, S. S., & Park, C. Y. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8065-6_8 · Cited by 1
Current Insights in the Cellular and Molecular Biology of Chronic Myelomonocytic Leukemia
Itzykson, R., Droin, N. M., & Solary, É. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.19 · Cited by 1
Weir, M. C. (2016) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Pediatric malignancies: update on sarcomas and leukemia development in children
Braun, B. S., & Lessnick, S. L. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.005 · Cited by 1
“In this case, the murine model recapitulates the human disease in a number of features, including a myeloproliferative phenotype, splenomegaly, and hypersensitivity of myeloid progenitors to cytokine stimulation [24].”
BackgroundResultSelf-citationEsposito, N. (2008) · Università degli Studi di Napoli Federico II · doi:10.6092/unina/fedoa/3382
“Recently, it was shown that expression of an oncogenic KRAS using a conditional knock-in line of mice efficiently induced an MPD that resembled human chronic myelomonocytic leukaemia (CMML) [30].”
BackgroundGenetic Modeling of Human Blood Cancers in Mice
Hu, Y., & Li, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_2
“topoietic system, K-ras induces a myeloproliferative disease, but it is not sufficient to induce AML (Braun et al., 2004; Chan et al., 2004).”
BackgroundHematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia
Niemeyer, C. M., & Locatelli, F. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch49
Drug Response and Resistance in Advanced NF1-Associated Cancers
Shannon, K. (2013) · Defense Technical Information Center (DTIC) · doi:10.21236/ada581891
Self-citationDefining RCE1 and ICMT as Therapeutic Targets in K-RAS-induced Cancer
Wahlstrom, A. M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Prognostic markers in pediatric leukemia and mechanisms of KRAS induced leukemogenesis
Staffas, A. (2013) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Too much ERK, not enough erythrocytes
Guadagno, T. M. (2004) · Blood · doi:10.1182/blood-2004-06-2461
The Importance of Isoprenylation and Nf1 Deficiency in K-RAS-induced Cancer
Sjogren, A.-K. M. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
뀀Ƞ THE FLT3 TYROSINE KINASE IN LEUKEMIA
Nordigården, A. (2013)
Hasserjian, R. P. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_32
Möröy, T., Patel, C. V., Peeters, J. K., Löwenberg, B., Göttgens, B., Meyer, S. E., Grimes, H. L., van der Reijden, B. A., Jansen, J. H., Gaudreau, M., et al. (2013)
Mediated by Ras Inhibition of Myeloid Differentiation Ral Is both Necessary and Sufficient for the
Darley, L., Omidvar, N., Pearn, L., Burnett, A. K., & Richárd (2014)
Standing at odds: mutated RAS and hematopoietic stem cells
Nafria, M., & Bonifer, C. (2019) · Haematologica · doi:10.3324/haematol.2019.230029
Targeting leukemic stem cells in a murine model of CALM-AF10 positive acute myeloid leukemia
Mandal, T. (2021) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-38905
Oncogenic Forms of ABL Family Kinases
Ren, R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68744-5_7
In the Pipeline: Emerging Therapy for MDS and MDS/MPN
Gill, H., Lee, E., & Mo, P. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_35
Juvenile myelomonocytic leukaemia, a disease of the hematopoietic development ?
Strullu, M. (2020) · theses.fr (ABES) · doi:10.70675/4c43b75ez3802z430bzad4ez2e83408fd47a
Decroocq, J. (2019) · theses.fr (ABES) · doi:10.70675/6e933875z3629z4e49z9d73z698f1f919e4c
Chromosomal and Genomic Alterations in Pediatric AML
Lamble, A. J., & Huang, B. J. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_2 · Cited by 1
Identificação de RNAs não codificadores longos regulados pelo oncogene KRAS em câncer de pâncreas
Corrêa, T. B. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-09042025-160757
Genetically Engineered Mice Harboring RAS Mutations as Models of Human Cancer: in Medias RAS
Zaks, T. Z., Jacobetz, M. A., & Tuveson, D. A. (2006) · Springer eBooks · doi:10.1007/1-4020-4708-8_12
“mutated in human malignancy is K-ras ( Bos 1989; Khosravi-Far and Der 1994).”
BackgroundSelf-citationLubeck, B. A. (2015) · Deep Blue (University of Michigan) · Cited by 1
Oncogene Function in Pre-Leukemia Stage of INV(16) Acute Myeloid Leukemia: A Dissertation
Xue, L. (2014) · eScholarship@UMassChan · doi:10.13028/m2d88n
“The CBF-SMMHC is a fusion protein with N-terminal amino acid (1-165) of”
BackgroundBerg, J. L., Perfler, B., Hatzl, S., Mayer, M.-C., Wurm, S., Uhl, B., Reinisch, A., Klymiuk, I., Tierling, S., Pregartner, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13535851
Lin, H.-T., Takagi, M., Kubara, K., Yamazaki, K., Michikawa, F., Okumura, T., Naruto, T., Morio, T., Miyazaki, K., Taniguchi, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26707643
Lin, H.-T., Takagi, M., Kubara, K., Yamazaki, K., Michikawa, F., Okumura, T., Naruto, T., Morio, T., Miyazaki, K., Taniguchi, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25622082
Lin, H.-T., Takagi, M., Kubara, K., Yamazaki, K., Michikawa, F., Okumura, T., Naruto, T., Morio, T., Miyazaki, K., Taniguchi, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25621892
Lin, H.-T., Takagi, M., Kubara, K., Yamazaki, K., Michikawa, F., Okumura, T., Naruto, T., Morio, T., Miyazaki, K., Taniguchi, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26707640
Forte, D., Barone, M., Morsiani, C., Simonetti, G., Fabbri, F., Bruno, S., Bandini, E., Sollazzo, D., Collura, S., Deregibus, M. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13684690
Coppin, E. (2015) · theses.fr (ABES) · doi:10.70675/6957c36dz8f27z48f3z8280z053c2d8e66ec
Caye‐Eude, A. (2018) · theses.fr (ABES) · doi:10.70675/5970456azb8a7z44a5zad25zbcef6aab00b1
Metadata
- Authors
- Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M.
- Affiliations
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Departments of Pediatrics and Laboratory Medicine and Comprehensive Cancer Center, University of California, San Francisco, CA 94143; Abramson Center for Cancer Research, University of Pennsylvania, Philadelphia, PA 19104; Section of Hematology/Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637; and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
- Corresponding author
- Shannon, Kevin M.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-12-29
- Volume
- 101
- Issue
- 2
- Pages
- 597-602
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC327193
- OpenAlex
- W2017349699
- Cited by
- 299
- References
- 53
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 10 · 2023: 3 · 2022: 5 · 2021: 12 · 2020: 7 · 2019: 12 · 2018: 9 · 2017: 8 · 2016: 13 · 2015: 8 · 2014: 24 · 2013: 16 · 2012: 17
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Frank A. Campini Foundation
- National Institutes of Health
- National Cancer Institute (CA 84221, R01CA072614, U01CA084221, U01CA084306, R37CA072614, CA84306, CA72614)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007636, T32 DK-07636)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- oncogenic KRAS, KRAS G12D, RAS mutations, myeloproliferative neoplasms, myeloid leukemia, hematopoietic cells, Ras-GTP, hyperproliferation, leukemogenesis, mouse model
- MeSH terms
- Animals, Bone Marrow Cells, Flow Cytometry, Karyotyping, Myeloproliferative Disorders, Genes, ras, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.